Savill. Omega-3 PUFAs of little benefit in secondary prevention. Practitioner 2014 ; 258 (1769): 7

Omega-3 PUFAs of little benefit in secondary prevention

20 Mar 2014Pais-up subscribers

The use of omega-3 polyunsaturated fatty acid (PUFA) supplements in patients with coronary heart disease (CHD) does not reduce major cardiovascular events, a large meta-analysis has found. Fourteen randomised controlled trials were analysed. Overall, 16,338 CHD patients received omega-3 PUFAs and 16,318 patients acted as controls.

Paid-up subscribersThis article can be accessed only if you are a paid-up subscriber to The Practitioner.

To view current online and print subscription rates, and to contact the subscription department, click Subscribe today .

To buy this article (£25+tax) copy the article citation above and click Buy article